FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310161913> ?p ?o ?g. }

• W4310161913 endingPage "6414" @default.
• W4310161913 startingPage "6413" @default.
• W4310161913 abstract "Follicular lymphoma (FL) is typically indolent, but despite treatment, relapses and transformation to higher grade disease are common. Ionizing radiation therapy (RT) is a guideline-preferred treatment for localized disease, and FL can be exquisitely radiosensitive, as demonstrated by the potential for complete response (CR) to very low dose RT (VLDRT, 4Gy). Clinicodemographic factors associated with durable FL response to RT are crude and though there are many predictive models of response to rituximab or chemotherapy, there are no known genetic markers of FL radiosensitivity. We sought to define genetic signatures of radiosensitivity in FL patients. We analyzed a single institution database of FL patients (all stages) treated with RT between 2005-2021 and identified 98 patients with 101 tumors each having preexisting MSK-IMPACT, a targeted exon sequencing panel assaying up to 505 genes. We also identified an additional validation cohort of 12 patients who did not have pre-existing mutation data for which we performed de novo MSK-IMPACT. We used hierarchical clustering with Ward criterion, and using scree plot analysis, identified an optimal number of gene alteration clusters. Using logistic regression and Kaplan Meier analysis, we associated the presence of gene alterations with best response to RT between 2-6 months using Lugano criteria and local progression (LP), respectively. We used LASSO Cox regression to derive a parsimonious model relating gene alterations to local progression. Lastly, we mined gene interaction networks related to genetic interactions, RT response, and gene regulation to identify dysregulated gene networks. The median RT dose was 4Gy (range: 4-36Gy, with 57 tumors (56%) receiving 4Gy. 83 tumors (83%) were grade 1-2. 72 (71%) tumors were early-stage at the time of RT, and 65 (64%) tumors were the only active site of disease in a patient at the time of treatment. 69 (69%) tumors had a CR, and with median follow-up of 25 months, 26 (26%) had local progression after RT (Table 1). FL grade was not associated with alterations in any gene, but alterations in MEF2B and BCL2 were associated with more advanced stage at RT (p=0.004 and p=0.017, respectively). The most prevalent mutations were CREBBP (65%), KMT2D (51%), TNFRSF14 (50%), STAT6 (27%), EZH2 (25%), BCL2 (24%), IRF8 (23%) and FOXO1 (21%), many of which are known epigenetic transcription regulators. We identified 5 clusters of altered genes with most clusters having CREBBP alterations, but one BCL2 altered cluster without CREBBP alterations that had significantly shorter LP after RT (log-rank p=0.02). From LASSO regression modeling, CREBBP, STAT6, B2M, TNFRSF14, HIST1H1E, TP53, MEF2B, FOXO1 and BCL2 were retained, with CREBBP and BCL2 having the largest effect sizes, indicating that alterations of these two genes make the largest contribution to observed LP after RT. Coding mutations occurring within CREBBP were associated with increased odds of CR (Odds ratio: 3.02 (95% CI: 1.25-7.33, p=0.014)) and reduced LP (median LP for mutations 136 months vs wild-type 31 months, log-rank p=0.02). Because CREBBP has multiple functional domains, including a histone acetyltransferase (HAT) domain responsible for transcriptional regulation, we further sought to contextualize the alterations within CREBBP. HAT domain mutations show a significant association with reduced LP risk after RT (Hazard ratio:0.37 (95% CI: 0.15-0.89, p=0.019)) (Figure 1). This effect was even more pronounced for the cohort of tumors receiving VLDRT of only 4 Gy (n=56) (log-rank p=0.05), and we confirmed this effect in our validation cohort (log-rank p=0.05). Lastly, we identified subnetworks of interconnected genes that are enriched in apoptosis and the immune system regulation. Alterations in the HAT domain of CREBBP, which likely result in a loss of function, are associated with better response to RT. Genetically defined cluster signatures can be further explored to understand the additive effects of alterations in addition to CREBBP on treatment response. Additionally, as histone acetylation by CREBBP is implicated in the radiosensitivity of FL, it is possible that agents targeting epigenetic processes may have a role in increasing radiosensitivity during FL treatment. The genetic landscape of FL patients being treated with radiotherapy, especially VLDRT, may be incorporated into clinical decision making to improve patient and dose selection for RT. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310161913 created "2022-11-30" @default.
• W4310161913 creator A5007603376 @default.
• W4310161913 creator A5017049966 @default.
• W4310161913 creator A5018022811 @default.
• W4310161913 creator A5023759382 @default.
• W4310161913 creator A5024505450 @default.
• W4310161913 creator A5041344703 @default.
• W4310161913 creator A5048304251 @default.
• W4310161913 creator A5054664737 @default.
• W4310161913 creator A5058490970 @default.
• W4310161913 creator A5062492719 @default.
• W4310161913 creator A5067154927 @default.
• W4310161913 creator A5069295830 @default.
• W4310161913 creator A5070544922 @default.
• W4310161913 creator A5072492170 @default.
• W4310161913 creator A5074971164 @default.
• W4310161913 creator A5079976876 @default.
• W4310161913 date "2022-11-15" @default.
• W4310161913 modified "2023-09-30" @default.
• W4310161913 title "Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma" @default.
• W4310161913 doi "https://doi.org/10.1182/blood-2022-169501" @default.
• W4310161913 hasPublicationYear "2022" @default.
• W4310161913 type Work @default.
• W4310161913 citedByCount "0" @default.
• W4310161913 crossrefType "journal-article" @default.
• W4310161913 hasAuthorship W4310161913A5007603376 @default.
• W4310161913 hasAuthorship W4310161913A5017049966 @default.
• W4310161913 hasAuthorship W4310161913A5018022811 @default.
• W4310161913 hasAuthorship W4310161913A5023759382 @default.
• W4310161913 hasAuthorship W4310161913A5024505450 @default.
• W4310161913 hasAuthorship W4310161913A5041344703 @default.
• W4310161913 hasAuthorship W4310161913A5048304251 @default.
• W4310161913 hasAuthorship W4310161913A5054664737 @default.
• W4310161913 hasAuthorship W4310161913A5058490970 @default.
• W4310161913 hasAuthorship W4310161913A5062492719 @default.
• W4310161913 hasAuthorship W4310161913A5067154927 @default.
• W4310161913 hasAuthorship W4310161913A5069295830 @default.
• W4310161913 hasAuthorship W4310161913A5070544922 @default.
• W4310161913 hasAuthorship W4310161913A5072492170 @default.
• W4310161913 hasAuthorship W4310161913A5074971164 @default.
• W4310161913 hasAuthorship W4310161913A5079976876 @default.
• W4310161913 hasBestOaLocation W43101619131 @default.
• W4310161913 hasConcept C126322002 @default.
• W4310161913 hasConcept C143998085 @default.
• W4310161913 hasConcept C203014093 @default.
• W4310161913 hasConcept C206684579 @default.
• W4310161913 hasConcept C2777058707 @default.
• W4310161913 hasConcept C2779338263 @default.
• W4310161913 hasConcept C502942594 @default.
• W4310161913 hasConcept C509974204 @default.
• W4310161913 hasConcept C54355233 @default.
• W4310161913 hasConcept C71924100 @default.
• W4310161913 hasConcept C86803240 @default.
• W4310161913 hasConceptScore W4310161913C126322002 @default.
• W4310161913 hasConceptScore W4310161913C143998085 @default.
• W4310161913 hasConceptScore W4310161913C203014093 @default.
• W4310161913 hasConceptScore W4310161913C206684579 @default.
• W4310161913 hasConceptScore W4310161913C2777058707 @default.
• W4310161913 hasConceptScore W4310161913C2779338263 @default.
• W4310161913 hasConceptScore W4310161913C502942594 @default.
• W4310161913 hasConceptScore W4310161913C509974204 @default.
• W4310161913 hasConceptScore W4310161913C54355233 @default.
• W4310161913 hasConceptScore W4310161913C71924100 @default.
• W4310161913 hasConceptScore W4310161913C86803240 @default.
• W4310161913 hasIssue "Supplement 1" @default.
• W4310161913 hasLocation W43101619131 @default.
• W4310161913 hasOpenAccess W4310161913 @default.
• W4310161913 hasPrimaryLocation W43101619131 @default.
• W4310161913 hasRelatedWork W1501529729 @default.
• W4310161913 hasRelatedWork W2002128513 @default.
• W4310161913 hasRelatedWork W2072009397 @default.
• W4310161913 hasRelatedWork W2147384423 @default.
• W4310161913 hasRelatedWork W2411361939 @default.
• W4310161913 hasRelatedWork W2922501427 @default.
• W4310161913 hasRelatedWork W2953751035 @default.
• W4310161913 hasRelatedWork W3024914256 @default.
• W4310161913 hasRelatedWork W4200029042 @default.
• W4310161913 hasRelatedWork W2092874662 @default.
• W4310161913 hasVolume "140" @default.
• W4310161913 isParatext "false" @default.
• W4310161913 isRetracted "false" @default.
• W4310161913 workType "article" @default.